The Part D Enhanced Medication Therapy Management model will examine the effectiveness of selected Medicare Prescription Drug Plans at achieving the overall goals for medication therapy management programs, including improving compliance with medication protocols, reducing medication-related problems, increasing patients’ knowledge of their medications and boosting communication between prescribers, pharmacists, caregivers and patients.
“As part of our approach to building a healthcare delivery system that results in better care, smarter spending and healthier people, CMS will test changes to the Part D program to give prescription drug plans stronger incentives and flexibility to improve prescription drug safety and efficacy,” said Patrick Conway, MD, CMS’ deputy administrator for innovation & quality and CMO.
According to Dr. Conway, CMS is hopeful that the new model will help identify new, effective strategies to optimize medication use and improve care coordination in Medicare.
To read more about the Part D Enhanced Medication Therapy Management model, click here.
More articles on payer issues:
Religious leader claims Horizon BCBS “schemed” to exclude most Catholic hospitals from new plan
2 Georgia health systems to discontinue Medicare Advantage plan
Anthem merger filing reveals new details about Cigna deal
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
